Shares of Dynavax Technologies Corp. jumped 34 percent after the company reported two-year data from a Phase II/III trial showing that its disease-modifying allergy drug, Tolamba, significantly reduced symptoms compared to placebo. (BioWorld Today)

Shares of Dynavax Technologies Corp. jumped 34 percent after the company reported two-year data from a Phase II/III trial showing that its disease-modifying allergy drug, Tolamba, significantly reduced symptoms compared to placebo. (BioWorld Today)

Cytokinetics Inc. is raising $33 million through a stock sale to fund clinical development of its lead products, including a heart failure drug that recently started a Phase I trial. (BioWorld Today)

Cytokinetics Inc. is raising $33 million through a stock sale to fund clinical development of its lead products, including a heart failure drug that recently started a Phase I trial. (BioWorld Today)